다발성경화증 치료를 위한 인터페론 베타의 산업적 생산

다국어 초록 (Multilingual Abstract)

Multiple sclerosis is a chronic disorder commonly occurred in the central nervous system and is an autoimmune disease. Corticosteroids are used as a short-term treatment for multiple sclerosis, but they cause side effects. Therefore, interferon beta having antiviral and anti-inflammatory effects, is used for long-term treatment. Interferon beta-1a, produced in Chinese hamster ovary cells, is glycosylated upon biosynthesis and forms glycoform, which is similar to naturally occurring protein. However, its process has disadvantages such as slow cell growth, low yield and high contamination possibility. Also, recombinant Escherichia coli is widely used for the production of interferon beta-1b due to its rapid growth and easy process scale up, but it lacks post-translational modification, leading to low activity. In addition, the produced Interferon beta-1b might cause protein aggregation due to misfolding. Alternatively, yeast can be used as a production host possessing N-glycosylation activity. Therefore, the choice of expression system in the production of interferon beta should be carefully selected in relation to the quality and yield.

목차 (Table of Contents)

• Abstract
• 1. INTRODUCTION
• 2. 본론
• 3. CONCLUSION
• REFERENCES

참고문헌 (Reference)

1 Rice, G., "Treatment with interferon beta-1b improves quality of life in multiple sclerosis" 26 : 276-282, 1999

2 Harde, D. R., "The use of zwittergent 3-14 in the purification of recombinant human interferon-${\beta}$ ser17 (Betaseron)" 15 : 31-37, 1995

3 Singh, V., "The paradigm of Th1 and Th2 cytokines" 20 : 147-161, 1999

4 Beck, R. W., "The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis" 329 : 1764-1769, 1993

5 Kieseier, B. C, "The Mechanism of action of interferon-${\beta}$ in relapsing multiple sclerosis" 25 : 491-502, 2011

6 Mattanovich, D., "Stress in recombinant protein producing yeasts" 113 : 121-135, 2004

7 Mattanovich, D., "Recombinant Gene Expression. Methods in Molecular Biology (Methods and Protocols)" Humana Press 329-358, 2012

8 Sahdev, S., "Production of active eukaryotic proteins through bacterial expression systems: A review of the existing biotechnology strategies" 307 : 249-264, 2008

9 Spearman, M., "Production and glycosylation of recobinant ${\beta}$-interferon in suspension and cytopore microcarrier cultures of CHO cells" 21 : 31-39, 2005

10 Prisms, S, "PRISMS-4: Long-term efficacy of interferonbeta- 1a in relapsing MS" 56 : 1628-, 2001

11 Ashnagar, F., "Optimizing primary recovery and refolding of human interferon-b from Escherichia coli inclusion bodies" 12 : 26-34, 2014

12 Soldan, S. S., "Neuroimmune Pharmacol" Springer 239-255, 2008

13 Cree, B. A. C, "Multiple sclerosis genetics" 122 : 193-209, 2014

14 Goldenberg, M. M, "Multiple Sclerosis Review" 37 : 175-184, 2012

15 Arnold, S., "Method for the purification of interferon-B. US Patent, 424/85.6; 530/351"

16 Sandig, V., "Mammalian cells: Production of recombinant proteins: Novel microbial and eukaryotic expression systems" Wiley-VCH Weinheim 233-252, 2005

17 Simon, J. H., "Magnetic resonance studies of intramuscular interferon ${\beta}$-1a for relapsing multiple sclerosis" 43 : 79-87, 1998

18 Li, D. K., "Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-${\beta}$ 1 a in relapsing-remitting multiple sclerosis" 46 : 197-206, 1999

19 Goffeau, A., "Life with 6000 genes" 274 : 546-567, 1996

20 Romanov, V. P., "Isolation of human interferon ${\beta}1b$ (Ser17) expressed in E. coli with the use of ion-exchange chromatography" 37 : 292-297, 2011

21 Dhib-Jalbut S., "Interferon-${\beta}$ mechanisms of action in multiple sclerosis" 74 : S17-S24, 2010

22 Paty, D., "Interferon beta?1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double?blind, placebo?controlled trial" 43 : 662-662, 1993

23 McCormick, F. R. A. N. K., "Inducible expression of amplified human beta interferon genes in CHO cells" 4 : 166-172, 1984

24 Mastrangeli, R., "In vitro biological characterization of IFN-${\beta}$-1a major glycoforms" 25 : 21-29, 2014

25 Zago, P., "Improving human interferon-${\beta}$ production in mammalian cell lines by insertion of an intronic sequence within its naturally uninterrupted gene" 52 : 191-198, 2009

26 Villela Dr. A., "Human interferon Β1ser17: Coding DNA synthesis, expression, purification and characterization of bioactive recombinant protein" 2 : 1948-5948, 2010

27 Song, K., "Glycoengineering of interferon-${\beta}$ 1a improves its biophysical and pharmacokinetic properties" 9 : e96967-, 2014

28 Feizi, A., "Genome-scale modeling of the protein secretory machinery in yeast" 8 : e63284-, 2013

29 Aricescu, A. R., "Expression of recombinant glycoproteins in mammalian cells: Towards an integrative approach to structural biology" 23 : 345-356, 2013

30 Skoko, N., "Expression and characterization of human interferon-${\beta}1$ in the methylotrophic yeast Pichia pastoris" 38 : 257-265, 2003

31 Weinshenker, B. G, "Epidemiology of multiple sclerosis" 14 : 291-308, 1996

32 Han, Y. K., "Enhanced interferon- ${\beta}$ production by CHO cells through elevated osmolality and reduced culture temperature" 25 : 1440-1447, 2009

33 Rodriguez, J., "Enhanced Production of Monomeric Interferon-${\beta}$ by CHO Cells through the Control of Culture Conditions" 21 : 22-30, 2005

34 Kamionka, M., "Engineering of therapeutic proteins production in Escherichia coli" 12 : 268-274, 2011

35 Chernajovsky, Y., "Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-${\beta}1$ gene fused to an SV40 early promoter" 3 : 297-308, 1984

36 La Mantia, L., "Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses" 34 : 199-203, 1994

37 Calabresi, P. A, "Diagnosis and management of multiple sclerosis" 70 : 1935-1944, 2004

38 Rao, D. V. K., "Cloning, high expression and purification of recombinant human Intereferon-${\beta}$-1b in Escherichia coli" 158 : 140-154, 2009

39 Spearman, M., "Cell Technology for Cell Products" Springer 71-85, 2007

40 Walsh, G, "Biopharmaceutical benchmarks 2014" 32 : 992-1000, 2014

41 Mohan, C., "Assessment of cell engineering strategies for improved therapeutic protein production in CHO cells" 3 : 624-630, 2008

42 Lai, T., "Advances in mammalian cell line development technologies for recombinant protein production" 6 : 579-603, 2013